Kinetics and quantification of antibacterial effects of beta-lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens

Infection, Supplement

Volumn 33, Issue 2, 2005, Pages 3-14

  Schaper, K J ^a   Schubert, S ^b   Dalhoff, A ^b  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CEFIXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERTAPENEM; FROPENEM; IMIPENEM; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PENEM DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; CEPHALOSPORIN; PENICILLIN G;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; PHARMACODYNAMICS; QUANTITATIVE ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; ANALYTICAL PARAMETERS; ANTIBACTERIAL ACTIVITY; BACTERIOSTASIS; CALCULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; EXPERIMENTAL DESIGN; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH RATE; IN VITRO STUDY; KINETICS; PHENOTYPE; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; RESPIRATORY TRACT INFECTIONS;

EID: 31444442398     PISSN: 01732129     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-8202-2     Document Type: Article

References (41)

1. Vogelman B, Craig WA: Kinetics of antimicrobial activity. J Pediatr 1986; 108: 835-840.
2. Craig WA, Ebert SC: Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; 74: 63-70.
3. Rolinson GN: Effect of β-lactam antibiotics on bacterial cell growth rate. J Gen Microbiol 1980; 120: 317-323.
4. Tuomanen E, Cozens R, Tosch W, Zak O, Tomaz A: The rate of killing of Escherichia coli by β-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 1986; 132: 1297-1304.
5. Dalhoff A, Gehl AE, Lode H: Kinetic in vitro studies of antibacterial effects of the combination of new penicillins and cefalosporins against Proteus vulgaris. Chemotherapy 1982; 28: 381-389.
6. Thonus IP, Fontijne P, Michel MF: Ampicillin susceptibility and ampicillin induced killing rate of Escherichia coli. Antimicrob Agents Chemother 1982; 22: 386-390.
7. Briceland LL, Pasko MT, Mylotte JM: Serum bactericidal rate as measure of antibiotic interactions. Antimicrob Agents Chemother 1987; 31: 679-685.
8. Stratton CW, Liu C, Ratner B, Weeks LS: Bactericidal activity of daptomycin (LY 146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 1987; 31: 1014-1016.
9. Dalhoff A: Influence of β-lactam antibiotics in vitro on mixed cultures of Escherichia coli and Streptococcus faecalis. Curr Microbiol 1982; 7: 269-274.
10. Tisdale JE, Pasko MT, Mylotte JM: Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve. Antimicrob Agents Chemother 1989; 33: 1500-1505.
11. Garraffo R, Drugeon HB, Dellamonica P, Bernard E, Lapaluz P: Determination of optimal dose regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother 1990; 34: 614-621.
12. Van der Voet GB, Mattie H, van Furth R: Comparison of the antibacterial activity of azlocillin and ticarcillin in vitro and in irradiated neutropenic mice. J Antimicrob Chemother 1985; 16: 605-613.
13. Brown MRW, Garrett ER: Kinetics and mechanisms of action of antibiotics on microorganisms. I. Reproducibility of Escherichia coli growth curves and dependence upon tetracycline concentration. J Pharm Sci 1964; 53: 179-183.
14. Garrett ER, Miller GH: Kinetics and mechanisms of action of antibiotics on microorganisms. III. Inhibitory action of tetracycline and chloramphenicol on Escherichia coli established by total and viable counts. J Pharm Sci 1965; 54: 427-431.
15. Garret, ER, Mielck JB, Seydel JK, Kessler HJ: Kinetics and mechanisms of action of drugs on microorganisms. VIII. Quantification and prediction of the biological activities of meta-and para-substituted N1-phenylsulfanilamides by microbial kinetics. J Med Chem 1969; 12: 740-745.
16. Seydel JK, Wempe E, Miller GH, Miller L: Kinetics and mechanisms of action of trimethoprim and sulfonamides, alone or in combination, upon Escherichia coli. Chemotherapy 1972; 17: 217-258.
17. Seydel JK, Wempe E, Rosenfeld M: Bacterial growth kinetics of Escherichia coli and mycobacteria in the presence of brodimoprim and metioprim alone and in combination with sulfamerazine and dapsone. Chemotherapy 1983; 29: 249-261.
18. Rosenfeld M, Spannuth G, Wempe E, Kunz B, Bartels H, Visser K, Seydel JK, Ruschmeyer H-J: In vitro activity of the new quinoline derivative ciprofloxacin alone and in combination against various mycobacterium-, salmonella- and Escherichia coli strains. Arzneim-Forsch/Drug Res 1986; 36: 904-912.
19. Dalhoff A, Ullmann U: Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur J Clin Microbiol Infect Dis 1990; 9: 479-487.
20. Vogelmann B, Gudmundsson S, Legget J, Turnidge J, Eberts S, Craig WA: Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
21. Gerber AU: Impact of the antibiotic dosage schedule on efficacy in experimental soft tissue infections. Scand J Infect Dis 1990; 74 (Suppl.): 147-154.
22. Drusano GL, Craig WA: Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 (Suppl. 3): 38-44.
23. Dawson SJ, Reeves DS: Therapeutic monitoring, the concentration-effect relationship and impact on the clinical efficacy of antibiotic agents. J Chemother 1997; 9 (Suppl. 1): 84-92.
24. Craig WA: Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 636-642.
25. Leggett JE, Ebert S, Fantin B, Craig WA: Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1990; 74 (Suppl.): 179-184.
26. Rotschafter JC, Zabinski RA, Walker KJ: Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy 1992; 12: 64S-70S.
27. Neu HC: Carbapenems: special properties contributing to their activity. Am J Med 1985; 78 (Suppl. 6A): 33-40.
28. Ferrara A, Grassi G, Grassi FA, Piccioni PD, Grassi GG: Bactericidal activity of meropenem and interactions with other antibiotics. J Antimicrob Chemother 1989; 24 (Suppl. A): 239-250.
29. Nadler HL, Pitkin DH, Sheikh W: The post antibiotic effect of meropenem and imipenem on selected bacteria. J Antimicrob Chemother 1989; 24 (Suppl. A): 225-231.
30. Pankuch GA, Davies TA, Jacobs MR, Appelbaum PC: Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Antimicrob Agents Chemother 2002; 46: 42-46.
31. Dalhoff A, Thomson C: The art of fusion: from penams and cephems to penems. Chemotherapy 2003; 49: 105-120.
32. Andes D, Craig WA: Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19: 261-268.
33. Dalhoff A: Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999; 43 (Suppl. B): 51-59.
34. Dalhoff A, Schmitz FJ: In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Microbiol Infect Dis 2003; 22: 203-221.
35. Van Bambeke F, Michot JM, van Eldere J, Tulkens PM: Quinolones in 2005, an update. Clin Microbiol Infect 2005; 11: 256-280.
36. Potel G, Chau NP, Pangon B, Fantin B, Vallois JM, Faurisson F, Carbon C: Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding. Antimicrob Agents Chemother 1991; 35: 2085-2090.
37. Potel G, Caillon J, leGallou F, Bugnon D, leConte P, Raza J, Lepage JY, Baron D, Drugeon H: Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis. Antimicrob Agents Chemother 1992; 36: 744-750.
38. Hermsen ED, Harde LB, Sprandel K, Rodvold KA, Rotschafer JC: Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2005; 49: 685-689.
39. Schubert S, Dalhoff A, Stass H, Ullmann U: Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations. Infection 2005; 33 (Suppl. 2): 15-21.
40. MacGowan A, Rogers C, Bowker K: The use of in vitro pharmacodynamics models of infection to optimise fluoroquinolone dosing regimens. J Antimicrob Chemother 2000; 46: 163-170.
41. Dalhoff A: Pharmacodynamics of quinolones. Drugs 1995; 49 (Suppl. 2): 197-199.